Clinical Trial: A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221188) titled 'A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH' on Oct. 15.

Brief Summary: This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Non-alcoholic Fatty Liver Disease

Intervention: DRUG: Efimosfermin Alfa

Efimosfermin Alfa will be administered

DRUG: Placebo

Placebo will be administered

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GlaxoSmithKline ...